Introduction: Revisional bariatric surgery is sometimes required due to inadequate weight loss, reoccurrence of comorbidities, or long-term complications following a previous bariatric procedure. However, the use of revisional surgery, based on the status of medical comorbidities, warrants further investigation. As such, the aim of this study was to examine medication usage for hypertension (HTN), type 2 diabetes mellitus (T2DM), and dyslipidemia (DLP) pre and postrobot-assisted Roux-en-Y gastric bypass (RRYGB) surgery as a revisional bariatric procedure. Materials and Methods: This is a retrospective review of a prospectively maintained database that included patients who underwent a RRYGB as a revisional procedure due to inadequate weight loss between January 2008 and January 2016 at the

No abstract